Data Sheet (Cat.No.TP2246)

TargetMol

Endothelin-1 (1-15), amide, human

Chemical Properties



CAS No. :

Formula: C70H109N17O23S5

Molecular Weight: 1717.04

Storage: Keep away from moisture
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Endothelin-1 is one of the there isoforms of endothelin (identified as ET-1, -2, -3) with varying regions of expression and binding to at least four known endothelin receptors, ETA, ETB1, ETB2 and ETC.
Targets(IC50)	Others
In vitro	Endothelins are the most potent vasoconstrictors known. In a healthy individual, a delicate balance between vasoconstriction and vasodilation is maintained by endothelin and other vasoconstrictors as well as nitric oxide, prostacyclin, and other vasodilators. The ubiquitous distribution of endothelin peptides and receptors implicates its involvement in a wide variety of physiological and pathological processes in the body. Among numerous diseases potentially occurring from endothelin dysregulation are several types of cancer, cerebral vasospasm following subarachnoid hemorrhage, arterial hypertension, and other cardiovascular disorder, pain mediation, type II diabetes, etc [2][3].

Solubility Information

Solubility	H2O: Soluble, 1% acetic acid: Soluble, (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.5824 mL	2.912 mL	5.824 mL
5 mM	0.1165 mL	0.5824 mL	1.1648 mL
10 mM	0.0582 mL	0.2912 mL	0.5824 mL
50 mM	0.0116 mL	0.0582 mL	0.1165 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Moulton KS, Heller E, Konerding MA et al. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999 Apr 6;99(13):1726-32.
O'Reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997 Jan 24;88(2):277-85.
Kisker O, Becker CM, Prox D et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001 Oct 15; 61(20):7669-74.